Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global Cervical Cancer Diagnostic Test Market worth USD 9.46 Billion by 2021

Zion Market Research
Posted on: 28 Sep 16

Zion Research has published a new report titled “Cervical Cancer Diagnostic Test Market (Pap Smear Tests, Colposcopy, HPV Testing, Endocervical Curettage (ECC) and Others) for Hospitals, Laboratories and Other End-users - Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 – 2021”.  According to the report, the global cervical cancer diagnostic market accounted for USD 6.70 billion in 2015 and is expected to reach USD 9.46 by 2021, growing at a CAGR of around 5.9% between 2015 and 2021. 

Cervical cancer is an abnormal growth of cervical cells in the cervix. Cervical cancer commonly spread through a virus termed as human papilloma virus (HPV). Most of the cervical cancer is caused due to HPV 16 and HPV 18 virus. The same viruses are also responsible for causing anal cancer and penile cancer in men. However, HPV 6 and HPV 11 are commonly associated with causing genital warts. With the growing number of cervical cancer diagnostic tests such as Pap smear tests, HPV testing and colposcopy for early detection, the demand of such market is described as highly competitive with high growth rate.

Get free Sample Report @ https://www.zionmarketresearch.com/sample/cervical-cancer-diagnostic-test-market

Browse the full "Cervical Cancer Diagnostic Test Market (Pap Smear Tests, Colposcopy, HPV Testing, Endocervical Curettage (ECC) and Others) for Hospitals, Laboratories and Other End-users - Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 – 2021" report at https://www.zionmarketresearch.com/report/cervical-cancer-diagnostic-test-market

The global cervical cancer diagnostic test market was expected to witness the highest growth over the forecast period due to increasing percentage of HPV infected female population across the globe. According to the Centers for Disease Control and Prevention (CDC), six million people in the U.S. acquire HPV each year. At least 20 million already have it, and more than half of all sexually-active adults will be infected during their lifetime. Furthermore increasing the incidence of weakened immune system coupled with certain life history is also considered as a major governing factor which promotes the cause of cervical cancer in female and thus promotes the cervical cancer diagnostic market. Moreover, many lifestyle-related factors, such as having multiple sex partners, smoking, obesity, unsafe sex with inherited HPV-positive patient, are estimated to drive the cervical diagnostics market. However, lack of education regarding the prevalence of cervical cancer and the unwillingness of the female population to undergo cervical cancer prognosis would hinder the growth of the market. In addition, prevention of HPV done by HPV vaccination is can also act as restraining factor in a growth of cervical cancer diagnostic market.

Inquire more about this report @ https://www.zionmarketresearch.com/inquiry/cervical-cancer-diagnostic-test-market

Based on the test, the global market of cervical cancer diagnostic test is bifurcated into five types: Pap smear tests, colposcopy, HPV testing, endo-cervical curettage (ECC) and others (cone biopsy and loop electrosurgical excision procedure (LEEP). In terms of revenue, the Pap smear tests segment accounted for the largest share of approximately more than 50% of the total cervical cancer diagnostic tests market in 2015. This demand is expected to continue within the forecast period. Factors attributed to this growth is dominated by the economical price of Pap smear test. Similarly, the HPV testing market is forecast to grow at the fastest growth rate of approximately more than 9% from 2015 to 2021 of the cervical cancer diagnostic tests market.

Based on end-user, the global market of cervical cancer diagnostic test is bifurcated into three types: hospitals, laboratories, and others. In end-user segment, the hospital was the leading segment in 2015 and this segment is expected to continue its dominance during the forecast period due to the continuous rise in HPV virus across the globe.

In terms of geography, North America was the leading market for cervical cancer diagnostic test in 2015 in terms of revenue due to the availability of technologically advanced computer-guided screening tests. In addition increasing number of geriatric population in North America and Europe serves as a major driving factor for the growth of cervical cancer diagnostic test market in this region. Furthermore, lifestyle-related factor such as smoking, having multiple sex partners is very common in the U.S., and European countries. Moreover, cervical cancer diagnostic test has the huge opportunity in emerging market like Asia Pacific, Latin America due to the public awareness, increase disposable income, government initiatives, and healthcare infrastructure.

Browse detail report with in-depth TOC @ https://www.zionmarketresearch.com/report/cervical-cancer-diagnostic-test-market

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global cervical cancer diagnostic test market include Abbott Laboratories, Becton, Dickinson and Company, Femasys, Inc., Hologic, Inc., Guided Therapeutics, Inc., OncoHealth Corp., Quest Diagnostics, Inc., Roche Diagnostics, QIAGEN, and Zilico Ltd.

For more information:
www.zionmarketresearch.com/news/global-cervical-cancer-diagnostic-test-market

Editor's Details

Allan Leonetti
Zion Market Research
www.zionmarketresearch.com
3863103803
allan.l@zionmarketresearch.com

Last updated on: 28/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.